Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
4.160
0.00 (0.00%)
Aug 5, 2026, 4:00 PM EDT - Market closed
Molecular Partners AG Employees
Molecular Partners AG had 134 employees as of December 31, 2025. The number of employees decreased by 25 or -15.46% compared to the previous year.
Employees
134
Change (1Y)
-25
Growth (1Y)
-15.46%
Revenue / Employee
n/a
Profits / Employee
-$539,838
Market Cap
152.39M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 134 | -25 | -15.46% |
| Dec 31, 2024 | 159 | -9 | -5.37% |
| Dec 31, 2023 | 168 | -8 | -4.45% |
| Dec 31, 2022 | 175 | 12 | 7.41% |
| Dec 31, 2021 | 163 | 18 | 12.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| LENZ Therapeutics | 152 |
| Cibus | 118 |
| Nkarta | 108 |
| Caribou Biosciences | 97 |
| Aardvark Therapeutics | 40 |
| Milestone Pharmaceuticals | 38 |
| Jyong Biotech | 27 |
| Unicycive Therapeutics | 22 |
MOLN News
- 20 days ago - Molecular Partners doses first patients in MP0317 combination study - TheFly
- 20 days ago - Molecular Partners Advanced Phase 2 Study Of MP0317 In Cholangiocarcinoma; Stock Up - Nasdaq
- 21 days ago - Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference - GlobeNewsWire
- 4 weeks ago - Molecular Partners To Advance MP0726 For First Human Imaging In H2,2026; Provides MP0712 Update - Nasdaq
- 4 weeks ago - Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics - GlobeNewsWire
- 4 weeks ago - Molecular Partners, Orano Med doses first patient in MP0712 study - TheFly
- 4 weeks ago - Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712 - GlobeNewsWire
- 2 months ago - Molecular Partners to hold trial-in-progress presentations on Phase 1/2a study - TheFly